Clinical trials: Urothelial Carcinoma
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Transitional Cell Carcinoma of Urinary Bladder
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
The purpose of this study is to define the optimal management of localised transitional cell carcinoma (TCC) of the urinary bladder. The main objective is to evaluate whether chemoradiation is superior to radiotherapy alone.
- Trial name
- NCT00330499
- Testing
- Cisplatin, External beam radiation treatment
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 67 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Recurrent Bladder Cancer, Stage III Bladder Cancer
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery.
- Conditions
- Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT01382706
- Testing
- docetaxel, lapatinib ditosylate, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Urothelial Carcinoma
Predictive Factorsfor Final Pathologic Ureteral Sections
To identify preoperative predictive factors for final ureteral section invasion after radical cystotomie (RC) and to validate significant factors on an external independent cohort.
- Trial name
- CYSTECTOMEN (NCT03677544)
- Testing
- laparoscopic approach with an extended pelvic lymph
- Where
- France
- Volunteers
- 748 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft…
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Urothelial Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03071328
- Testing
- Isovue-M 200
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy
- Trial name
- NCT07441499
- Testing
- Multi-Component Liquid Biopsy for Urothelial Carcinoma
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Second Hospital
Bladder Cancer
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005047
- Testing
- cisplatin, doxorubicin hydrochloride, methotrexate
- Where
- 74 sites in United States, Canada
- Volunteers
- 521 people
- Sponsor
- SWOG Cancer Research Network
Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer.
- Conditions
- Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT01639521
- Testing
- cisplatin, gemcitabine hydrochloride, methotrexate
- Sponsor
- University of Southern California
Urothelial Carcinoma, Kidney Cancer
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
This is a phase 2 study of the drug denosumab for the management bone metastases from urothelial cancer. The purpose of this study is to find out how effective denosumab is in the management of bone metastases from urothelial…
- Conditions
- Urothelial Carcinoma, Kidney Cancer, Ureter Cancer, Bladder Cancer
- Trial name
- NCT03520231
- Testing
- Denosumab, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Advanced Urothelial Carcinoma
Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
This is a Phase II, single arm study. All subjects will receive Zanzalintinib 60 mg orally once daily until progression per RECIST 1.1 or intolerable toxicities or patient/investigator decision to discontinue study therapy.
- Trial name
- NCT07185945
- Testing
- Zanzalintinib
- Volunteers
- 44 people
- Sponsor
- Guru Sonpavde
Urinary Bladder Neoplasms, Urologic Neoplasms
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC).
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Trial name
- FORAY (NCT07827612)
- Testing
- Vepugratinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Eli Lilly and Company
Upper Urinary Tract Urothelial Carcinoma
Translational Cancer Observational Protocol
Observational study on relapse occurrence and on the quality of life in patients who underwent nephroureterectomy surgery
- Trial name
- NCT06169436
- Testing
- Nephroureterectomy
- Where
- Italy
- Volunteers
- 1,250 people
- Sponsor
- IRCCS San Raffaele
Metastatic Urothelial Cancer
Paclitaxel and TAK-228 in Urothelial Carcinoma
Phase II Multicentre, single arm, open label study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations
- Trial name
- NCT03745911
- Testing
- Paclitaxel and TAK-228
- Where
- 5 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Urothelial Carcinoma
Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS
Genetron Uro V1 perform mutation detection of 17 genes and methylation detection of 1 gene by using urine samples and tumor tissue samples.
- Trial name
- NCT04994197
- Testing
- Observational study only - no intervention
- Where
- 9 sites in China
- Volunteers
- 970 people
- Sponsor
- Ruijin Hospital
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Urothelial Carcinoma, Advanced Cancer
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
- Trial name
- NCT03507166
- Testing
- RC48-ADC
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- RemeGen Co., Ltd.
Transitional Cell Carcinoma, Transurethral Resection
BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer
Instillation of Bacillus of Calmette-Guerin (BCG) into the urinary bladder (intravesical administration) improves rates of disease recurrence and progression after transurethral resection (TUR) of high risk, non-muscle-invasive…
- Trial name
- NCT06462001
- Testing
- Bacillus Calmette-Guerin Vaccine Intravesical, Mitomycin
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Ovarian Cancer, Triple-negative Breast Cancer
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in…
- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Trial name
- NCT03992131
- Testing
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- pharmaand GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.